Singapore, Nov. 4 -- Zuellig Pharma, a leading healthcare solutions company in Asia, has announced the strategic acquisition of a specialised clinical supply facility in Hangzhou, China, strengthening its clinical sourcing capabilities to better support domestic and international clinical trials.

The Hangzhou facility holds a Drug Distribution License (DDL), enabling Zuellig Pharma to provide local clinical sourcing of comparator drugs and concomitant medications in China. This strengthens Zuellig Pharma's ability to offer compliant, in-market sourcing solutions while streamlining billing processes and creating opportunities for value-added tax (VAT) savings for clinical trial sponsors.

Strategically located in the heart of Yangtze Rive...